医学
不利影响
内科学
移植物抗宿主病
临床终点
胃肠病学
置信区间
移植
外科
随机对照试验
作者
Corey S. Cutler,Stephanie Joi Lee,Sally Arai,Marcello Rotta,Behyar Zoghi,Aleksandr Lazaryan,Aravind Ramakrishnan,Zachariah Michael DeFilipp,Amandeep Salhotra,Wanxing Chai‐Ho,Rohtesh S. Mehta,Trent Peng Wang,Mukta Arora,Iskra Pusic,Ayman A Saad,Nirav Niranjan Shah,Sunil Abhyankar,Carlos R. Bachier,John Patrick Galvin,Annie Im
出处
期刊:Blood
[Elsevier BV]
日期:2021-07-15
卷期号:138 (22): 2278-2289
被引量:397
标识
DOI:10.1182/blood.2021012021
摘要
Belumosudil, an investigational oral selective inhibitor of Rho-associated coiled-coil-containing protein kinase 2 (ROCK2), reduces type 17 and follicular T helper cells via downregulation of STAT3 and enhances regulatory T cells via upregulation of STAT5. Belumosudil may effectively treat patients with chronic graft-versus-host disease (cGVHD), a major cause of morbidity and late nonrelapse mortality after an allogeneic hematopoietic cell transplant. This phase 2 randomized multicenter registration study evaluated belumosudil 200 mg daily (n = 66) and 200 mg twice daily (n = 66) in subjects with cGVHD who had received 2 to 5 prior lines of therapy. The primary end point was best overall response rate (ORR). Duration of response (DOR), changes in Lee Symptom Scale score, failure-free survival, corticosteroid dose reductions, and overall survival were also evaluated. Overall median follow-up was 14 months. The best ORR for belumosudil 200 mg daily and 200 mg twice daily was 74% (95% confidence interval [CI], 62-84) and 77% (95% CI, 65-87), respectively, with high response rates observed in all subgroups. All affected organs demonstrated complete responses. The median DOR was 54 weeks; 44% of subjects have remained on therapy for ≥1 year. Symptom reduction with belumosudil 200 mg daily and 200 mg twice daily was reported in 59% and 62% of subjects, respectively. Adverse events (AEs) were consistent with those expected in patients with cGVHD receiving corticosteroids and other immunosuppressants. Sixteen subjects (12%) discontinued belumosudil because of possible drug-related AEs. Belumosudil, a promising therapy for cGVHD, was well tolerated with clinically meaningful responses. This trial was registered at www.clinicaltrials.gov as #NCT03640481.
科研通智能强力驱动
Strongly Powered by AbleSci AI